Kodiak Sciences to Unveil Phase 3 Retina Data at AAO 2026

The company’s presentation schedule, running from October 9 to October 12, 2026, centers on the first scientific disclosure of the DAYBREAK study. Dr. Charles Wykoff is set to present findings on October 9, detailing how both Zenkuda and tabirafusp-ted achieved non-inferior vision gains compared to aflibercept at the one-year mark. These results, initially released in late September, represent a critical milestone for the Palo Alto-based firm as it maneuvers through its precommercial phase.

Beyond the wet AMD data, the conference will feature updates on the GLOW2 study regarding Zenkuda’s efficacy in diabetic retinopathy, presented by Dr. Margaret Chang on October 10. Additionally, Dr. Edmund Tsui will lead the discussion on the Phase 1b APEX study for KSI-101, targeting macular edema secondary to inflammation. For Kodiak, these sessions serve to validate its broader portfolio, which includes three late-stage assets designed to compete in the multibillion-dollar anti-VEGF market.